An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: Results of the STOP study

Current Medical Research and Opinion

Volumn 28, Issue 8, 2012, Pages 1369-1379

  Aaron, Lorne E ^a   Morris, Thomas J ^b   Jahshan, Paulette ^c   Reiz, Joseph L ^d  

^a HÔPITAL CHARLES LEMOYNE   (Canada)

^b Guelph General Hospital   (Canada)

^c Lynden Hills Research   (Canada)

^d PURDUE PHARMA L P   (United States)

Author keywords

Cognitive status; Muscarinic antagonist; Overactive bladder; Oxybutynin; Patient satisfaction; Urinary incontinence

Indexed keywords

OXYBUTYNIN; UNCLASSIFIED DRUG; UROMAX;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; COGNITION; CONFUSION; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DELIRIUM; DIZZINESS; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HUMAN; JOB SATISFACTION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; NOCTURIA; OPEN STUDY; OVERACTIVE BLADDER; PATIENT SATISFACTION; PHARYNGITIS; PHYSICIAN; SLEEP QUALITY; TREATMENT OUTCOME; URINARY FREQUENCY; URINE INCONTINENCE; XEROSTOMIA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALGORITHMS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; PERSONAL SATISFACTION; PHYSICIANS; URINARY BLADDER, OVERACTIVE;

EID: 84864562568     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.709837     Document Type: Article

References (42)

1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
2. Shaw C. A systematic review of the literature on the prevalence of sexual impairment in women with urinary incontinence and the prevalence of urinary leakage during sexual activity. Eur Urol 2002;42:432-40
3. Simeonova Z, Milsom I, Kullendorff AM, et al. The prevalence of urinary incontinence and its influence on the quality of life in women from an urban Swedish population. Acta Obstet Gynecol Scand 1999;78:546-51
4. Milsom I, Stewart W, Thü roff J. The prevalence of overactive bladder. Am J Manag Care 2000;6(11 Suppl):S565-73
5. Resnick NM, Yalla SV, Laurino E. The pathophysiology of urinary incontinence among institutionalized elderly persons. N Engl J Med 1989;320:1-7
6. Geirsson G, Fall M, Lindstrom S. Subtypes of overactive bladder in old age. Age Aging 1993;22:125-31
7. Managing incontinence due to detrusor instability. Drug Ther Bull 2001;39:59-64
8. Brown JS, Vittinghoff E, Wyman JF, et al. For the Study of Osteoporotic Fractures Research Group. Urinary incontinence: does it increase the risk for falls and factures? J Am Geriatr Soc 2000;48:721-5
9. Brubaker L, Shull B. EGGS for patient-centered outcomes. Int Urogynecol J 2005;16:171-3
10. Brubaker L, Chapple C, Coyne KS, et al. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006;68:3-8
11. Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54:740-64
12. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009;19:380-94
13. Patel B, Bavendam T, Badlani G. Use of antimuscarinics in the elderly. Scientific World Journal 2009;9:459-65
14. FDA Pediatric Advisory Committee. Update to the Committee: Oxybutynin Central Anticholinergic Effects. April 11, 2007. Available from: http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4295s-03-Oxybutynin%20slides- files/frame.htm
15. Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: A randomized controlled trial. JAMA 1998;280:1995-2
16. Bemelmans BLH, Kiemeney LALM, Debruyne FMJ. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. Eur Urol 2000;37:709-13
17. Abrams P, Freeman R, Anderström C, et al. A. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-10
18. Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J 1999;10:283-9
19. Shumaker SA, Wyman JF, Uebersax JS, et al. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Qual Life Res 1994;3:291-306
20. Uebersax JS, Wyman JF, Shumaker SA, et al. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Neurourol Urodyn 1995;14:131-9
21. Chancellor MB, Pittsburgh PA, Sathyan G, et al. Spit study to compare different formulations of oxybutynin. J Urol 1999;161:256a
22. Reiz JL, Salem P, Darke AC. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin. J Clin Pharmacol 2007;47:351-7
23. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state" a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr Res 1975;12:189-98
24. StatsDirect Ltd. StatsDirect statistical software. http://www. statsdirect.com. England: StatsDirect Ltd 2005;
25. Miettinen OS, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4:213-26
26. Clark CM, Sheppard L, Fillenbaum GG, et al. The CERAD Investigators. Arch Neurol 1999;56:857-62
27. Abrams P, Artibani W, Gajewski JB, et al. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006;68:17-28
28. Abrams P, Andersson K-E, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148: 565-78
29. McDowell BJ, Engberg S, Sereika S, et al. Effectiveness of behavioral therapy to treat incontinence in homebound older adults. J Am Geriatr Soc 1999;47:309-18
30. Engberg S, Sereika S, Weber E, et al. Prevalence and recognition of depressive symptoms among homebound older adults with urinary incontinence. J Geriatr Psychiatr Neurol 2001;14:130-9
31. Engberg S, Sereika SM, McDowell BJ, et al. Effectiveness of prompted voiding in treating urinary incontinence in cognitively impaired homebound older adults. J Wound Ostomy Continence Nurse 2002;29: 252-65
32. Schnelle JF, Traughber B, Sowell VA, et al. Prompted voiding treatment of urinary incontinence in nursing home patients. A behavior management approach for nursing home staff. J Am Geriatr Soc 1989;37: 1051-7
33. Griffiths DJ, McCracken PN, Harrison GM, et al. Cerebral aetiology of urinary urge incontinence in elderly people. Age Ageing 1994; 23:246-50
34. Lacker TE, Wyman JF, McCarthy TC, et al. Randomized, placebo-controlled trial of cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 2008;56:862-70
35. Corcos J, Casey R, Patrick A, et al. A double-blind randomized dose-response study comparing daily doses of 5, 10, and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. BJU Int 2005; 97:520-7
36. Barkin J, Corcos J, Radomski S, et al. A randomized, double-blind, parallelgroup comparison of controlled-and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 2004;26:1026-36
37. Purdue Pharma. Long-term open-label extension of a randomized, double-blind parallel group comparison of the efficacy and safety of oral controlled-release oxybutynin and immediate-release oxybutynin for urinary incontinence. Report No. 018-005 Addendum; September 2004. Data on file
38. Bolge SC, McDonnell DD, Chen A, et al. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder. Curr Med Res Opin 2007;23:1903-12
39. Chu FM, Dmochowski RR, Lama DJ, et al. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: A subanalysis of the data from the OPERA trial. Am J Obstet Gynecol 2005;192:1849-55
40. Diokno A, Sand P, Labasky R, et al. Long-term safety of extendedrelease oxybutynin chloride in a community-dwelling population of participants with overactive bladder: A one year study. Int Urol Nephrol 2002;34:43-9
41. Yarker YE, Goa KL, Fitton A. Oxybutynin: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-62
42. Brubaker L, Chapple C. Introduction. Urology 2006;68:1-2